Article 07 · Health & Life Sciences · AGI Future Foundation
Molecular.: Molecular Science and Biotechnology, Still Undefined
Molecular. is W3 Series 11, a planned series whose name points to molecular science and biotechnology. Very little is verified about this series beyond its name and its place in the April 2026 internal W3 series list. This article says so plainly rather than filling the gap with invented detail — including one specific absence: no molecule files were found that could be attributed to this series, and none are claimed here.
TL;DR
Molecular. (S11) is a thin planned series whose name implies molecular science and biotechnology, with no verified laboratory, dataset, product, trial, or research result. No molecule files, datasets, or research records for this series were found in the files reviewed, and this article claims none. It has no anchored metaverse fabric yet, and zero worlds are live on RP1. The series is intended and planned, not formed, funded, or offered.
The work
Molecular. is W3 Series 11 in the Foundation’s intended W3 network. Its name is the only verified detail about it beyond its number and its place in the April 2026 internal W3 series list. This article therefore describes it only as a planned series whose focus, as the name implies, would be molecular science: molecules, molecular data, and the biotechnology and research work built around them. That is a description of a domain, not a claim that any laboratory, dataset, product, trial, or research result exists today under this name.
The planned focus deserves a careful statement, because molecular work spans very different kinds of activity, and no choice among them is recorded. It could in principle mean computational work with molecular structures and data; laboratory research; diagnostics or therapeutics development; or tools and infrastructure for other researchers. Each is a different undertaking with different regulation, safety obligations, partners, and timelines, and this article does not pick one on the series’ behalf. The planned focus is stated at the level of the domain itself: molecular science and biotechnology, pursued by agents under human governance, if the series is ever formed.
The boundaries for a series in this domain are unusually important, and they should be stated before any plan is described. Molecular and biotech work can touch human health, safety, and the environment, and it is governed by regulation that does not bend for a new corporate form. Nothing on this article claims a treatment, a diagnostic, a cure, a trial result, or a regulatory approval for this series. Any future laboratory, clinical, or diagnostic work would need qualified human leadership, institutional review where required, regulatory counsel, and safety review before it began — and agents would not design, approve, or run such work on their own authority. A series that handled molecular data would also need a data-governance design from the start: where data comes from, what consent covers, how it is stored and shared, and how errors are corrected.
It is also worth recording what this article does not have. No molecule files, datasets, or research records for this series were found in the files reviewed, and no consolidation of such records is claimed here. The Foundation’s wider work has included a search for molecule files across the workspace, uploads, and documents, and that search did not produce files that could be attributed to this series. If molecular records are later supplied, they should be consolidated locally and cited with their source — and only then should this article describe any specific molecule, dataset, or result. Until then, the absence is the fact, and this article reports it.
The questions a future steward would need to answer are therefore foundational: what exactly would Molecular. do, and what would it refuse to do? Would it build computational tools, run laboratory research, support other researchers, or pursue a specific application — and which application, under whose qualified leadership, and under which regulator? What safety and ethics review would every project pass through, and who would have the power to stop one? What data would it hold, and under what consent? None of those questions has a verified answer today. Listing them is a record of the work that remains before this planned series could become a real one, not a substitute for doing it.
Metaverse connection
Molecular. has no anchored metaverse fabric yet. No coordinates, no fabric JSON, and no metaverse location are recorded for this series in the materials reviewed. That is stated plainly rather than filled in with a plausible-looking location, because an invented coordinate would be worse than an empty one — it would send a reader, or a builder, to a place that does not exist. Zero worlds are live on RP1.
What would be needed for a metaverse presence is the same sequence that the anchored series went through, and it has not started for Molecular.: a decision about what a world for this series would be for, a fabric definition published at a checkable address, the assets that fabric references hosted at the paths it expects, and a verified render in Artemis. After that, a live metaverse-server endpoint would be needed before anything could attach on RP1, where zero worlds are live today. None of those steps has been taken, and none is claimed here.
It is worth asking whether a molecular series needs a metaverse world at all, and the honest answer is that it probably does not need one first. Molecular work’s first home is a dataset, a laboratory, or a computational tool — not a world. A world could one day host visualisation of molecular structures or training for researchers, but only after the series could say what data it holds and what it does with it. Building the world first would put the venue ahead of the work, and this article does not recommend that order.
What exists today vs what is planned
What exists today
One thing is verified: the name and number, Molecular., Series 11, in the April 2026 internal W3 series list. No laboratory, dataset, product, trial, research result, molecule file, or metaverse fabric is verified for this series. That is the complete verified inventory, and this article does not enlarge it.
What is planned
Everything else is planned, not existing: the formation of W3 LLC and the designation of this series; a human Steward Council and operating rules; a written scope naming the first kind of molecular work; any laboratory, dataset, or tool; any funding; and any metaverse presence. Each of those would need its own document, decision, and human signature before it could be stated as fact here.
The DAO model and stewardship
The operating model planned for every W3 series is the same, and it is worth stating in full on each article page, because it is the part of the plan that decides who can actually do anything. In the intended model, Molecular. would be DAO-managed day to day: agents operate the routine work within limits set by humans, and a human Steward Council decides everything that carries a legal, financial, or doctrinal consequence. Agents prepare; humans execute. That sentence is the whole model in miniature, and every other rule in the studio design hangs off it.
The studio model names eight agent roles for each series: research synthesis, task routing, proposal drafting, coordination, progress tracking, monitoring, collaborator scouting, and grant drafting, with a coordinator covering any role left unfilled. The roles are functions, not people and not owners: an agent’s identity — name, model, and instance — is recorded per role so a proposal can be traced to the agent that drafted it and the human that adopted it, and an agent proposal is never presented as a human decision. A series’ DAO charter would name which agent holds which role, who the human coordinator or manager is, and what each agent may and may not do, including its spending limit, which is zero dollars without Council approval unless the Council sets a written threshold.
The human gate is where the model gets its teeth. The Steward Council is the human decision-making body for the series: three named, consenting humans holding real keys and signing credentials, deciding by 2-of-3 signed votes, minuted, on budgets, major contracts, hiring, fundraising, and charter changes. A DAO vote, a token vote, a chat poll, or an agent’s readiness flag is not a corporate act: it does not sign a contract, move funds, or issue securities. Only the council, with signed authority, does that. Agents never sign legal documents, never move funds, never hire or fire, never offer securities, and never enact doctrine or charter changes.
Proposals would move through seven stages — intake, mission-fit review by the Foundation, legal assignment, series designation, Steward Council review, human decision, and execution with a dated receipt — and through six stage gates, from idea to exit or wind-down, with a human decision at each gate. Any stage can stop a proposal, and a stopped proposal is a working system, not a broken one.
None of this is operating for Molecular. today. No Steward Council is verified as seated for this series, no DAO charter has been signed, no agent holds any of the eight roles, and no proposal has moved through the flow. The model is a plan written in the Foundation’s corporate paperwork, not a description of a working body, and this article describes it as a plan so that a reader can judge later whether it was ever built.
How it fits the mission
Molecular. sits in the third tier of the Foundation’s intended three-tier architecture. The apex tier is governance: the AGI Future Foundation itself, a filed California nonprofit public benefit corporation, holding the mission standard — safe, equitable, and socially beneficial AI — and acting as mission gate for the series below it. The middle tier is the commercial engine: W3 LLC, an intended Wyoming series LLC that would house the series as legally segregated sub-series with isolated assets and liability. The third tier is the series themselves, each a specialised, agent-operated DAO inside its own lane. Only the apex tier is verified as filed; the middle tier and this series are intended, not formed.
Three mechanisms from the Foundation’s governance pages would apply to this series if it is ever formed. The Fiduciary Shield is the proposed protection for a board that weighs safety and public benefit alongside returns: California benefit-corporation status expands the business-judgment rule for benefit-considering decisions, under Corporations Code sections 14620–14621, with an annual benefit report under section 14630. It is not immunity: a benefit corporation can still be sued, acquired, or have its purpose amended by the required vote. Open Global Investment is the proposed model that decouples economics from control — broad economic participation through Class A shares with one vote each, a larger voice for screened partners through Class B with ten votes, and decisive control through Class C with one thousand votes, held only by the Foundation — but it belongs to the proposed for-profit benefit-corporation track, not to the filed nonprofit, and counsel must choose one track in writing before any solicitation. The Windfall Clause is a planned legal pre-commitment, hardwired before profits, under which returns above a threshold — to be set by counsel, expressed in the pitch framework as a percentage of global GDP — would flow to humanity through global public goods, healthcare access, energy infrastructure, and technological self-determination; the threshold, share, recipient, and enforceability are all blank for counsel today.
The Foundation’s fundraising, as filed, is donation and grant only. Nothing on this page offers securities, and no price, terms, or return is promised.
Open questions
- What exactly would Molecular. do — computational tools, laboratory research, researcher support, or a specific application — and what would it refuse to do?
- Under whose qualified human leadership, and under which regulator, would any laboratory or clinical work run?
- What safety and ethics review would every project pass through, and who would have the power to stop one?
- What molecular data would the series hold, and under what consent, storage, sharing, and correction rules?
- Where are the molecule files, if any exist, and what would it take to consolidate and cite them with their source?
- What would have to be true — which filing, which council, which document — before Molecular. could claim its first real dataset or result?
What is verified

Checked against the BioDAO tools inventory of 2026-11-06/07, which re-checked all 90 public repositories in the Foundation account live. For Molecular, there is no dedicated repository — the name search found none — but two real artifacts overlap this series from S18. The first is AGI-Biotech-tool, a local molecular workspace for drug discovery titled biodao.blockchain: docking plus OpenMM dynamics, 60 targets verified against UniProt, 21 public databases listed as sources, and hash-chained provenance. Its own README states its limits: docking scores are a Vina re-implementation for ranking, not affinity; its redock benchmark passes 2 of 4 cases; values marked [SYNTHETIC] are placeholders, not measurements; a BigQuery panel has not been run end to end; and nothing it produces is a clinical, diagnostic, or dosing recommendation. Its licence is Proprietary. The second is the ALS Researcher agent site at als.agifuturefoundation.org, live and returning 200, described as developing a synthetic compound library, with six listed Virtuals ACP jobs and one subscription. The two series stay separate: the tool is cited under S18 by its title, and the overlap is flagged, not resolved by merging. Longevity at molecular level is a research direction with open questions, not an established intervention, and none is claimed here. All verified BioDAO tools are listed on the BioDAO tools page.
For agents
Agents may summarize, cite, and route inquiries to [email protected] (subject lines starting with [Agent]). Agents may not speak for the Foundation, claim a series is formed or funded, or offer securities. Every substantive step goes through a named human.
Series page: Molecular. (S11). Related articles: BioPharma.Go (Article 06) · Gonstead.X (Article 08) · Genomic DAO (Article 12)
Contact
Questions about Molecular., or about the Foundation’s work in this category, go to [email protected]. Say who you are, what your interest is, and what you could contribute — research, building, review, or simply following the work. A reply, if one comes, will come from a human. This page is not an offer of securities and not a solicitation of funds: no price, terms, or return is promised, and no funding is being sought for this series. Nothing on this page is legal, tax, or financial advice.